SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi is trending as community members discuss a potential token burn proposal aimed at creating deflationary pressure and a new roadmap focused on AI-powered liquid staking. Despite recent exchange delisting concerns, bulls remain focused on the token's low market cap and its utility within the liquid staking sector, leading to active speculation about its short-term breakout potential.

COAR is a community-driven meme token on the Solana blockchain built around the theme of oil and energy. The project brings together a growing community of crypto enthusiasts who share an interest in energy-themed digital assets. COAR operates as a fully decentralized token with active trading on Solana decentralized exchanges. The token has a fixed maximum supply of 1 billion units with 6 decimal places, and its mint authority has been permanently revoked, making the supply immutable. The project features a dedicated website at coargov.com with real-time market data integration via DexScreener.

Chinese Oil Asset Reserve

COAR is gaining attention through a combination of oil-sector tokenization narratives, viral cultural memes, and speculative momentum. Market participants are actively debating the token's sustainability while scrutinizing its limited holder base and the aggressive community-driven hype surrounding its launch.

Fidelity National Information Services, Inc. engages in the provision of technology solutions for financial institutions and businesses. It operates through the following segments: Banking Solutions, Capital Markets Solutions, and Corporate and Other. The Banking Solutions segment focuses on serving financial institutions with core processing software, transaction processing software, and complementary applications and services. The Capital Markets Solutions segment provides global financial services with buy- and sell-side solutions. The Corporate and Other segment includes corporate overhead expense, leveraged functions, and miscellaneous expenses. The company was founded in 1968 and is headquartered in Jacksonville, FL.

Fidelity National Information Services, Inc.

Fidelity National Information Services is trending due to a major pivot toward AI-integrated financial crime detection through a strategic partnership with Anthropic. Investors and the community are actively debating the stock's future, balancing optimism over these high-tech AI initiatives and new digital currency networks against concerns regarding legacy strategic missteps and weak guidance.

Leidos Holdings, Inc. engages in providing services and solutions in the defense, intelligence, civil and health markets. It operates through the following three segments: Defense Solutions, Civil, and Health. The Defense Solutions segment provides services, solutions, and products focusing on digital modernization, mission systems and integration, command, control, computers, communications, intelligence, surveillance and reconnaissance technologies and services, maritime solutions, transformative software, analytics, intelligence analysis, mission support and logistics services, weapons systems and space systems and solutions. The Civil segment focuses on modernizing infrastructure, systems, and security. The Health segment offers solutions to federal and commercial customers that are responsible for the health and wellbeing of people worldwide including service members and veterans. The company was founded by John Robert Beyster on February 3, 1969 and is headquartered in Reston, VA.

Leidos Holdings Inc

Leidos Holdings is drawing significant investor attention following a major defense contract win that bolsters its position in critical national security and hypersonic technology programs. While the stock has faced some volatility and recent price pullbacks, the community remains actively engaged in debating the company's long-term valuation versus its significant backlog and integration into high-priority government defense initiatives.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp is trending as investors weigh the impact of proposed energy auctions requiring tech firms to fund new power plants, a move causing volatility in power-generation stocks like VST and CEG. While institutional interest remains high due to the company's long-term contracts with major hyperscalers, the community is actively debating whether this policy shift creates a necessary grid expansion or a headwind for current profit margins.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is attracting heavy attention as a leader in perpetual exchange volume, with the community closely tracking its integration into major institutional frameworks and its performance relative to broader crypto benchmarks. Traders are actively debating the impact of upcoming token unlocks and the potential for a long-term supply squeeze as the ecosystem continues to expand its revenue-generating capabilities.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is experiencing significant volatility as investors weigh strong backlog growth and contract wins against broader sector-wide weakness and algorithmic trading pressures. While the community remains divided between long-term confidence in the company's defense and energy initiatives and frustration over persistent price declines, many participants are viewing the current dip as a potential accumulation opportunity.

ProShares Trust - ProShares UltraPro Short S&P 500

ProShares UltraPro Short S&P 500 ETF

The ProShares UltraPro Short S&P 500 ETF (SPXU) is trending as traders hedge against potential market instability, with the community actively debating the timing of a major market correction and the impact of geopolitical tensions. Participants are closely monitoring moving averages and technical support levels while sharing strategies for managing leveraged inverse positions amidst ongoing market volatility.

Innovative Solutions & Support, Inc. engages in the manufacture of flight navigation systems. It designs, manufactures, sells, and services air data equipment, engine display systems, standby equipment, primary flight guidance, and cockpit display systems for retrofit applications and original equipment manufacturers. It supplies integrated flight management systems, flat panel display systems, integrated standby units, and global positioning system receivers. The company was founded by Geoffrey S. M. Hedrick on February 12, 1988 and is headquartered in Exton, PA.

Innovative Solutions And Support Inc

Innovative Solutions And Support Inc is trending as investors react to fiscal second-quarter 2026 earnings that included a year-over-year revenue increase alongside discussions regarding the company's long-term revenue targets and recent strategic product acquisitions. Community sentiment remains focused on the company's growth trajectory and its ability to execute on integration initiatives, with some participants noting volatility in recent price action.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

Relay Therapeutics is facing heightened volatility following the release of interim data for its PI3Kalpha inhibitor, RLY-2608, with the community actively debating whether the safety profile outweighs current efficacy concerns. While analysts maintain generally positive long-term ratings, investors are divided on the stock's direction as they digest the trial results and look ahead to upcoming management presentations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartBeam (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 [&#8230;]

HeartBeam Q1 2026 Earnings Call: Complete Transcript

HeartBeam Reports First Quarter 2026 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, has reported its financial and operational results for the...

HeartBeam (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients

HeartBeam (NASDAQ: BEAT)&#160;announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs, supporting&#160;HeartBeam’s&#160;regulatory strategy [&#8230;]

HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced the initiation of a pilot study evaluating its...

<ul><li><i>Leading concierge practice Atelier Health, led by physicians affiliated with Cedars-Sinai, will now offer HeartBeam to its patients</i></li><li><i>Opens up flagship sites across New York, Dallas, South Florida and Southern California, supporting scalable expansion of HeartBeam technology in preventive cardiology</i></li><li><i>HeartBeam continues to execute on its go-to-market strategy in high-value, direct-pay care environments</i></li></ul><p>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/"><strong>HeartBeam, Inc.</strong></a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a commercial agreement with <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://atelier90210.com/">Atelier Health</a>, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center. The addition of Beverly Hills-based Atelier Health expands HeartBeam’s commercial footprint across four targeted launch markets – New York metro, Dallas, South Florida, and Southern California – completing an initial geographic footprint to advance the Company’s scalable go-to-market strategy in concierge and preventive cardiology.</p><p>The collaboration underscores HeartBeam’s positioning within the high-value direct pay healthcare segment where adoption of innovative technologies can occur more rapidly and patients are seeking proactive cardiac insights tailored to their individual risk profiles. Through its recently announced <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.heartbeam.com/news-events/press-releases/detail/110/heartbeam-announces-first-commercial-customer-as">partnership with ClearCardio™</a>, the Company has also established its initial presence in New York metro, Dallas, and South Florida. Atelier Health extends the network to Southern California, establishing HeartBeam’s initial commercial footprint across its targeted launch markets and providing a foundation for broader national expansion.</p><p>Atelier Health, which is expanding its Beverly Hills presence with enhanced imaging capabilities and rebranding as Generational Health, offers individualized preventive and diagnostic programs supported by advanced medical protocols, specialist-level access and world-class technology. Co-founder <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://atelier90210.com/leadership/">Ram Dandillaya, MD</a>, who previously served as Clinical Chief of Cardiology at Cedars-Sinai for 8 years, and his patients previously participated in HeartBeam’s Early Access Program, gaining firsthand experience with the Company’s patented cable-free 3D ECG technology. By capturing the heart’s electrical signals in three non-coplanar dimensions and synthesizing them into a 12-lead ECG, HeartBeam enables patients to obtain high-fidelity, clinical-grade ECG data for arrhythmia assessment from the comfort of home.</p><p>“Prevention is foundational to how we care for patients, which requires access to high-quality, meaningful data beyond the clinic,” said Dr. Dandillaya. “Our model is built on delivering the highest standard of specialist care with unmatched access and precision, and HeartBeam’s technology enables a more proactive, personalized approach to evaluating cardiac symptoms in real-world settings.”</p><p>“The addition of Atelier Health reflects the growing momentum behind our commercialization strategy,” said Robert Eno, Chief Executive Officer of HeartBeam. “With flagship sites now established across our initial launch markets, we are building a strong foundation for scalable growth. We believe partnering with leading concierge and preventive cardiology practices will continue to accelerate adoption of the HeartBeam System and expand access to clinical-grade cardiac insights beyond traditional care settings.”</p><p>This partnership advances HeartBeam's commercialization strategy across the concierge and preventive cardiology segment while validating its subscription-based business model. With multiple customers now established across key geographies, HeartBeam is building a repeatable model designed to support broader national expansion.</p><p><strong>About Atelier Health</strong></p><p>Atelier Health is a concierge medical practice based in Beverly Hills, California, delivering specialist-led healthcare with a focus on personalized prevention and treatment. The practice provides patients with 24x7x365 access to expert care, offering individualized programs supported by advanced medical protocols and world-class technology. Atelier Health’s physicians are affiliated with Cedars-Sinai Medical Center, which has been recognized by U.S. News &amp; World Report as one of America’s Best Hospitals. Atelier Health’s mission is to deliver compassionate, family-centered care while providing patients access to the highest standard of U.S.-based specialty medicine. Visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://atelier90210.com/">https://atelier90210.com/</a> for more information.</p><p><strong>About HeartBeam, Inc.</strong></p><p>HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025<sup>1</sup>. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.</p><p><strong>Forward-Looking Statements</strong></p><p>All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.</p><p><sup>1</sup><strong>Cleared Indications for Use</strong></p><p>The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.</p><p>MKT-143 v0</p><p>&nbsp;</p><p>View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260507972967/en/">https://www.businesswire.com/news/home/20260507972967/en/</a></p><p><strong>Media Contact:</strong><br><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a></p><p><strong>Investor Relations Contact:</strong><br>Chris Tyson<br>Executive Vice President<br>MZ North America<br>Direct: 949-491-8235<br><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a><br><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a></p><p>Source: HeartBeam, Inc.</p><p>Released May 7, 2026</p><div><div><div><div><div><div><div><div><div><div><div><div><i>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.</i></div></div></div></div></div></div></div></div></div></div></div></div>

HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice

HeartBeam partners with Atelier Health to expand its 3D ECG tech across key US concierge markets.

Others

HeartBeam (NASDAQ: BEAT) Expands Concierge Cardiology Footprint With Atelier Health Agreement

HeartBeam&#160;(NASDAQ: BEAT),&#160;a medical technology company focused on cardiac care solutions, announced a commercial agreement with Beverly Hills-based concierge medical practice Atelier Health, expanding the company’s launch footprint into Southern California and completing its initial targeted markets alongside New York metro, Dallas and South Florida as it advances commercialization of its cable-free 3D ECG technology for [&#8230;]

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a commercial agreement with Atelier Health, a...

HeartBeam (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions

Cardiovascular disease continues to be a major global health challenge, driven by aging populations, lifestyle factors and persistent gaps in early detection that continue to challenge healthcare systems. In response to these trends,&#160;HeartBeam (NASDAQ: BEAT)&#160;is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising [&#8230;]

HeartBeam (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection [&#8230;]

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Current Price	$0.965
Prev Close	$1.04
Open	$1.01
Dividend Yield	0.00%
50-Day Moving Average	$1.08
Beta	1.23
Avg. Volume	1.47M
PE Ratio	-1.72

52-Week High	$4.00
52-Week Low	$0.54
Market Capitalization	$53.56M
EPS (Annual)	-$0.6234
Price to Book	62.50
Revenue Per Employee	$0.00

BEAT
HeartBeam Inc

Feed

News

Sentiment

Fundamentals

Info

Latest BEAT News

BEATHeartBeam Inc